BRPI0519996A2 - processo para formar atorvastatina amorfa - Google Patents

processo para formar atorvastatina amorfa

Info

Publication number
BRPI0519996A2
BRPI0519996A2 BRPI0519996-4A BRPI0519996A BRPI0519996A2 BR PI0519996 A2 BRPI0519996 A2 BR PI0519996A2 BR PI0519996 A BRPI0519996 A BR PI0519996A BR PI0519996 A2 BRPI0519996 A2 BR PI0519996A2
Authority
BR
Brazil
Prior art keywords
atorvastatin
solvent
amorphous atorvastatin
form amorphous
agent
Prior art date
Application number
BRPI0519996-4A
Other languages
English (en)
Inventor
Antone John Debettencourt Iii
Peter Robert Rose
Evgenyi Yur'evich Shalaev
George Joseph Quallich
Carl Bernard Ziegler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35954050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0519996(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0519996A2 publication Critical patent/BRPI0519996A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCESSO PARA FORMAR ATORVASTATINA AMORFA. A presente invenção refere-se a um processo para formar atorvastatina amorfa compreendendo as etapas de dissolver atorvastatina em um solvente não hidroxílico e remover o solvente por secagem por congelamento, assim como processos de dissolver atorvastatina em um solvente hidroxílico com um agente solubilizante ou um agente alcalinizante ou um antioxidante e remover o solvente por secagem por congelamento para dar atorvastatina amorfa.
BRPI0519996-4A 2004-10-28 2005-10-12 processo para formar atorvastatina amorfa BRPI0519996A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62308604P 2004-10-28 2004-10-28
PCT/IB2005/003173 WO2006046109A1 (en) 2004-10-28 2005-10-12 Process for forming amorphous atorvastatin

Publications (1)

Publication Number Publication Date
BRPI0519996A2 true BRPI0519996A2 (pt) 2009-04-07

Family

ID=35954050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519996-4A BRPI0519996A2 (pt) 2004-10-28 2005-10-12 processo para formar atorvastatina amorfa

Country Status (16)

Country Link
US (4) US7939675B2 (pt)
EP (1) EP1807055A1 (pt)
JP (1) JP2008517992A (pt)
KR (1) KR20070067175A (pt)
CN (1) CN101048141A (pt)
AR (1) AR051144A1 (pt)
AU (1) AU2005298383A1 (pt)
BR (1) BRPI0519996A2 (pt)
CA (1) CA2585836A1 (pt)
IL (1) IL182474A0 (pt)
MX (1) MX2007004722A (pt)
NZ (1) NZ554541A (pt)
RU (1) RU2007115543A (pt)
TW (1) TW200624419A (pt)
WO (1) WO2006046109A1 (pt)
ZA (1) ZA200702965B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
WO2009013633A2 (en) * 2007-07-20 2009-01-29 Actavis Group Ptc Ehf Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
CN101973922B (zh) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
AU2014277744B2 (en) * 2010-04-16 2017-01-19 Cumberland Pharmaceuticals, Inc. Stabilized Statin Formulations
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
CN103917643B (zh) * 2011-11-22 2020-06-05 西门子医疗保健诊断公司 包含用于复原为校准和/或质量控制溶液的干燥试剂的设备，及其生产和使用方法
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
MX2020012532A (es) * 2018-05-31 2021-04-28 Immunity Pharma Ltd Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela).
CN114569605B (zh) * 2022-03-10 2024-08-06 沈阳药科大学 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
ATE178794T1 (de) 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DK1148049T3 (da) 1995-07-17 2005-03-29 Warner Lambert Co Krystallinsk [R-(R*,R*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre-hemicalciumsalt (ATORVASTATIN)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DE69711391T2 (de) 1996-07-29 2002-11-07 Warner-Lambert Co., Morris Plains Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
FI106082B (fi) * 1996-12-05 2000-11-15 Nokia Networks Oy Menetelmä puhekanavan takaisinkytkemisen havaitsemiseksi sekä puheenkäsittelylaite
BR9813760A (pt) 1997-12-19 2000-10-03 Warner Lambert Export Limited Processo para a sìntese de 1,3-dióis
IN191236B (pt) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
AU6253700A (en) 1999-08-03 2001-02-19 Cottee Dairy Corporation Pty Limited Packaging
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
DE60018100T2 (de) 1999-11-17 2005-09-15 Teva Pharmaceutical Industries Ltd. Polymorphe form von atorvastatin-calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
AU4150602A (en) 2000-11-03 2002-06-03 Teva Pharma Atorvastatin hemi-calcium form vii
JP4234429B2 (ja) 2000-11-16 2009-03-04 テバ ファーマシューティカル インダストリーズ リミティド 水酸化カルシウムによる〔Ｒ（Ｒ＊，Ｒ＊）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸エステルの加水分解
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03005879A (es) 2000-12-27 2003-09-10 Ciba Sc Holding Ag Formas cristalinas de atorvastatina.
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (pt) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CN1524073A (zh) 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
US6598010B2 (en) 2001-07-11 2003-07-22 Uri Zefira Method for achieving accurate measurement of true weight
KR20040019043A (ko) 2001-07-30 2004-03-04 닥터 레디스 레보러터리즈 리미티드 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ
UA77990C2 (en) 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
WO2003068191A1 (en) * 2002-02-14 2003-08-21 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
JP4308021B2 (ja) 2002-03-18 2009-08-05 バイオコン・リミテッド 望ましい粒子サイズのアモルファスＨＭＧ−ＣｏＡレダクターゼ阻害剤
CA2491051A1 (en) 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof

Also Published As

Publication number Publication date
WO2006046109A1 (en) 2006-05-04
US20140155627A1 (en) 2014-06-05
AR051144A1 (es) 2006-12-20
MX2007004722A (es) 2007-06-15
JP2008517992A (ja) 2008-05-29
ZA200702965B (en) 2008-10-29
NZ554541A (en) 2011-01-28
US20110237642A1 (en) 2011-09-29
US7939675B2 (en) 2011-05-10
AU2005298383A1 (en) 2006-05-04
RU2007115543A (ru) 2008-12-10
CA2585836A1 (en) 2006-05-04
TW200624419A (en) 2006-07-16
IL182474A0 (en) 2007-07-24
CN101048141A (zh) 2007-10-03
US20120289576A1 (en) 2012-11-15
US8258315B2 (en) 2012-09-04
US8686163B2 (en) 2014-04-01
US20080269314A1 (en) 2008-10-30
EP1807055A1 (en) 2007-07-18
KR20070067175A (ko) 2007-06-27
US9056831B2 (en) 2015-06-16

Similar Documents

Publication Publication Date Title
BRPI0519996A2 (pt) processo para formar atorvastatina amorfa
BR112014000178A2 (pt) composições tópicas
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
BR112012010249A2 (pt) esterilização de hidrógeis biodegradáveis
BRPI0810431A8 (pt) Processo para utilização aperfeiçoada do potencial de produção de plantas transgênicas
BRPI0924622A2 (pt) composições para tratamento de tecidos, processo de fabricação, e método de uso.
UY30228A1 (es) Compuestos quimicos
BR112012025037A2 (pt) composições multifuncionais à base de sílica-gél, métodos de fazer as mesmas e métodos de usar as mesmas.
EA201000560A1 (ru) Способ получения органических нитратов
BR112015001655A2 (pt) método para purificar pelo menos uma saponina em uma solução, componente de produto de saponina qs-21 purificada, e, composição imunogênica
BRPI0817895A2 (pt) Composição de quitosana reticulável, processo para preparar um hidrogel de quitosana, hidrogel de quitosana, composição farmacêutica, e, agente imunológico
BRPI1100352A8 (pt) processo para a criação de canais de fluxo em um reservatório de carbonato, processo para remover danos do interior do poço em um reservatório de carbonato, e, solução
BRPI0921145A2 (pt) processo e método para remover bário de água.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CL2004000807A1 (es) Composicion de extraccion por solvente que comprende una o mas ortohidroxiarilaldoxinas y una o mas ortohidroxiarilcetoxinas y uno o mas modificadores de equilibrio para producir un grado de modificacion de las ortohidroxialrilaldoximas, de aproximad
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
AR050717A1 (es) Composiciones farmaceuticas
BR112013012795B8 (pt) processo de tratamento de produtos vegetais e composição
BRPI0411313A (pt) processo para formar atorvastatina amorfa
BRPI0719264B8 (pt) processo para a preparação de nebivolol
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0621384A2 (pt) Agente de tratamento agronômico, processo para obter agente de tratamento agronômico, material de planta, processo de tratamento agronômico
BRPI0509363A (pt) método para aumentar a eficácia preservativa de uma composição, composição oftálmica, método de tratamento de uma condição oftálmica e processo para produzir uma composição oftálmica
DE602006002146D1 (de) Aktivmatrixsubstrat, Verfahren zur Herstellung eines Aktivmatrixsubstrats, elektrooptische Vorrichtung und elektronische Vorrichtung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.